Search research articles
Contact Us
Filters
Showing results (151-160 of 196) with videos related to
Page
of 20
Sort By:
The Oncologist
|
May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC
Naoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial
François-Clément Bidard, Nicolas Kiavue, William Jacot, et al.
Nutrients
|
October 14, 2020
Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial
William Jacot, Antoine Arnaud, Marta Jarlier, et al.
NPJ Breast Cancer
|
February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomes
Michele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Clinical Pharmacology and Therapeutics
|
October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer
Alicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Angiogenesis
|
November 28, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)
Antoine Vasseur, Luc Cabel, Olivier Tredan, et al.
Theranostics
|
May 17, 2021
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment
Lindsay B Alcaraz, Aude Mallavialle, Timothée David, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2023
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
Angéline Galvin, Coralie Courtinard, Fanny Bouteiller, et al.
Breast (Edinburgh, Scotland)
|
May 20, 2026
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort
Marie Alexandre, Eva Teruel, Florence Dalenc, et al.
Journal of the National Cancer Institute
|
July 31, 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Davide Massa, Claudio Vernieri, Lorenzo Nicolè, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 196) with videos related to
Sort By:
Page
of 20
The Oncologist
|
May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBC
Naoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial
François-Clément Bidard, Nicolas Kiavue, William Jacot, et al.
Nutrients
|
October 14, 2020
Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial
William Jacot, Antoine Arnaud, Marta Jarlier, et al.
NPJ Breast Cancer
|
February 20, 2025
Temporal evolution of breast cancer brain metastases treatments and outcomes
Michele Bottosso, Gaia Griguolo, Severine Guiu, et al.
Clinical Pharmacology and Therapeutics
|
October 13, 2020
Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer
Alicja Puszkiel, Cécile Arellano, Christelle Vachoux, et al.
Angiogenesis
|
November 28, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)
Antoine Vasseur, Luc Cabel, Olivier Tredan, et al.
Theranostics
|
May 17, 2021
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment
Lindsay B Alcaraz, Aude Mallavialle, Timothée David, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 17, 2023
First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort
Angéline Galvin, Coralie Courtinard, Fanny Bouteiller, et al.
Breast (Edinburgh, Scotland)
|
May 20, 2026
Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort
Marie Alexandre, Eva Teruel, Florence Dalenc, et al.
Journal of the National Cancer Institute
|
July 31, 2024
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer
Davide Massa, Claudio Vernieri, Lorenzo Nicolè, et al.
Page
of 20